Publications

 


  • 656. Cancer mortality does not differ by antiarrhythmic drug use: A population-based cohort of Finnish men.

    Kaapu KJ, Rantaniemi L, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ, 2018

    Journal: Sci rep
    Reference: Jul 9;8(1):10308

    paper

  • 655. Prostate cancer screening: what can we learn from randomised trials?

    Auvinen A, 2018

    Journal: Transl Androl Urol
    Reference: Feb;7(1):12-17

    paper

  • 654. Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

    Murtola TJ, Vihervuori VJ, Lahtela J, Talala K, Taari K, Tammela TL, Auvinen A, 2018

    Journal: Br J Cancer
    Reference: 2018 May;118(9):1248-1254

  • 653. What is an acceptable false negative rate in the detection of prostate cancer?

    Verbeek JFM, Roobol MJ; ERSPC Rotterdam study group., 2018

    Journal: Transl Androl Urol
    Reference: Feb;7(1):54-60

    paper

  • 652. Screening for prostate cancer: are organized screening programs necessary?

    Roobol MJ, 2018

    Journal: Transl Androl Urol
    Reference: Feb;7(1):4-11

    paper

  • 651. Editorial Comment to Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.

    Alberts AR, Roobol MJ., 2018

    Journal: Int J Urol
    Reference: Mar;25(3):277

    paper

  • 650. Costs of screening for prostate cancer: Evidence from the Finnish Randomised Study of Screening for Prostate Cancer after 20-year follow-up using register data.

    Booth N, Rissanen P, Tammela TLJ, Taari K, Talala K, Auvinen A, 2018

    Journal: Eur J Cancer
    Reference: Apr;93:108-118

    paper

  • 649. Allopurinol and risk of benign prostatic hyperplasia in a Finnish population-based cohort.

    Kukko V, Kaipia A, Talala K, Taari K, Tammela TLJ, Auvinen A, Murtola TJ, 2017

    Journal: Prostate Cancer Prostatic Dis
    Reference: Dec 22.

  • 648. Prognostic factors of prostate cancer mortality in a Finnish randomized screening trial.

    Neupane S, Steyerberg E, Raitanen J, Talala K, Pylväläinen J, Taari K, Tammela TL, Auvinen A., 2017

    Journal: Int J Urol
    Reference: Mar;25(3):270-276

    paper

  • 647. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.

    Assel M, Sjöblom L, Murtola TJ, Talala K, Kujala P, Stenman UH, Taari K, Auvinen A, Vickers A, Visakorpi T, Tammela TL, Lilja H, 2017

    Journal: Eur Urol Focus
    Reference: Nov 11. pii: S2405-4569(17)30258-4

    paper

  • 646. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use

    Murtola TJ, Virkku A, Talala K, Stenman UH, Taari K, Tammela TLJ, Auvinen A, 2017

    Journal: J Urol
    Reference: Aug;198(2):305-309

    paper

  • 645. Prostate cancer screening in Europe and Asia.

    Zhang K, Bangma CH, Roobol MJ, 2017

    Journal: Asian J Urol
    Reference: Apr;4(2):86-95

    paper

  • 644. Summary statement on screening for prostate cancer in Europe.

    Heijnsdijk EAM, Bangma CH, Borràs JM, de Carvalho TM, Castells X, Eklund M, Espinàs JA, Graefen M, Grönberg H, Lansdorp-Vogelaar I, Leeuwen PJV, Nelen V, Recker F, Roobol MJ, Vandenbulcke P, de Koning HJ, 2018

    Journal: Int J Cancer
    Reference: Feb 15;142(4):741-746

    paper

  • 643. Stopping screening, when and how?

    Hugosson J, 2018

    Journal: Transl Androl Urol
    Reference: Feb;7(1):46-53

    paper

  • 642. Real-time Watchful Surveillance Looks Like Active Waiting.

    Bangma C, Roobol M, 2017

    Journal: Eur Urol
    Reference: Dec;72(6):908-909

    paper

  • 641. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer.

    Kweldam CF, Kümmerlin IP, Nieboer D, Steyerberg EW, Bangma CH, Incrocci L, van der Kwast TH, Roobol MJ, van Leenders GJ, 2017

    Journal: Mod Pathol
    Reference: Aug;30(8):1126-1132

  • 640. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.

    Gayet M, Mannaerts CK, Nieboer D, Beerlage HP, Wijkstra H, Mulders PFA, Roobol MJ, 2016

    Journal: Eur Urol Focus
    Reference: Aug 4. pii: S2405-4569(16)30107-9

    paper

  • 639. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.

    Hugosson J, Godtman RA, Carlsson SV, Aus G, Grenabo Bergdahl A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H, 2018

    Journal: Scand J Urol
    Reference: Feb;52(1):27-37

    paper

  • 638. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

    de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R, 2018

    Journal: Cancer
    Reference: Mar 15;124(6):1197-1206

    paper

  • 637. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?

    Alberts AR, Schoots IG, Bokhorst LP, Drost FH, van Leenders GJ, Krestin GP, Dwarkasing RS, Barentsz JO, Schröder FH, Bangma CH, Roobol MJ, 2017

    Journal: Eur Urol
    Reference: Jun 21. pii: S0302-2838(17)30514-6

    paper

  • 636. Additional benefit of using a risk-based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer.

    Chiu PK, Alberts AR, Venderbos LDF, Bangma CH, Roobol MJ, 2017

    Journal: BJU Int
    Reference: Sep;120(3):394-400

  • 635. Biopsy undergrading in men with Gleason score 6 and fatal prostate cancer in the European Randomized study of Screening for Prostate Cancer Rotterdam.

    Alberts AR, Bokhorst LP, Kweldam CF, Schoots IG, van der Kwast TH, van Leenders GJ, Roobol MJ., 2017

    Journal: Int J Urol
    Reference: Apr;24(4):281-286

  • 634. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.

    Roobol MJ, Verbeek JFM, van der Kwast T, Kümmerlin IP, Kweldam CF, van Leenders GJLH, 2017

    Journal: Eur Urol
    Reference: Jul;72(1):45-51

    paper

  • 633. Prostate cancer: Draft USPSTF 2017 recommendation on PSA testing – a sea-change?

    van der Kwast TH, Roobol MJ, 2017

    Journal: Nat Rev Urol
    Reference: Aug;14(8):457-458

    paper

  • 632. Prostate cancer-specific survival among warfarin users in the Finnish Randomized Study of Screening for Prostate Cancer.

    Kinnunen PTT, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A, 2017

    Journal: BMC Cancer
    Reference: Aug 29;17(1):585

    paper

  • 631. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.

    Saarimäki L, Hugosson J, Tammela TL, Carlsson S, Talala K, Auvinen A, 2017

    Journal: Eur Urol Focus
    Reference: Aug 10.

  • 630. Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

    Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R, 2017

    Journal: Ann Intern Med
    Reference: Sep 5.

    paper

  • 629. Estimate of opportunistic prostate-specific antigen testing in the Finnish Randomized Study of Screening for Prostate Cancer.

    Kilpeläinen TP, Pogodin-Hannolainen D, Kemppainen K, Talala K, Raitanen J, Taari K, Kujala P, Tammela TL, Auvinen A, 2017

    Journal: J Urol
    Reference: Jul;198(1):50-57

    paper

  • 628. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.

    Murtola TJ, Karppa EK, Taari K, Talala K, Tammela TL, Auvinen A, 2017

    Journal: Int J Cancer
    Reference: Jun 15;138(12):2820-8

  • 627. Antidiabetic drug use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

    Haring A, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen , 2017

    Journal: Scand J Urol
    Reference: Jan 13:1-11

    paper

  • 626. Reply from Authors re: Roderick C.N. van den Bergh, Declan G. Murphy, Henk G. van der Poel. Expectant Management for Prostate Cancer: Lessons from the Past, Challenges for the Future. Eur Urol 2016;70:767-8.

    Godtman RA, Stranne J, Hugosson J, 2016

    Journal: Eur Urol
    Reference: Nov;70(5):769-770

    paper

  • 625. Design-corrected variation by centre in mortality reduction in the ERSPC randomised prostate cancer screening trial.

    Hakama M, Moss SM, Stenman UH, Roobol MJ, Zappa M, Carlsson S, Randazzo M, Nelen V, Hugosson J, 2016

    Journal: J Med Screen
    Reference: Aug 9.

    paper

  • 624. Corrigendum re: “Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial” [Eur Urol 2016;70:566-73].

    Bergdahl AG, Wilderäng U, Aus G, Carlsson S, Damber JE, Frånlund M, Geterud K, Khatami A, Socratous A, Stranne J, Hellström M, Hugosson J, 2016

    Journal: Eur Urol
    Reference: Feb;71(2):e81

    paper

  • 623. Impact of cause of death adjudication on the results of the European prostate cancer screening trial.

    Walter SD, de Koning HJ, Hugosson J, Talala K, Roobol MJ, Carlsson S, Zappa M, Nelen V, Kwiatkowski M, Páez Á, Moss S, Auvinen A; ERSPC Cause of Death Committees, 2017

    Journal: Br J Cancer
    Reference: Jan 3;116(1):141-148

    paper

  • 622. What explains the differences between centres in the European screening trial? A simulation study.

    Nevalainen J, Stenman UH, Tammela TL, Roobol M, Carlsson S, Talala K, Schröder FH, Auvinen A, 2016

    Journal: Cancer Epidemiol
    Reference: Nov 24;46:14-19

    paper

  • 621. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.

    Carlsson SV, de Carvalho TM, Roobol MJ, Hugosson J, Auvinen A, Kwiatkowski M, Villers A, Zappa M, Nelen V, Páez A, Eastham JA, Lilja H, de Koning HJ, Vickers AJ, Heijnsdijk EA, 2016

    Journal: Cancer
    Reference: Nov 15;122(21):3386-3393

    paper

  • 620. Correction: Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.

    Auvinen A, Moss SM, Tammela TL, Taari K, Roobol MJ, Schröder FH, Bangma CH, Carlsson S, Aus G, Zappa M, Puliti D, Denis LJ, Nelen V, Kwiatkowski M, Randazzo M, Paez A, Lujan M, Hugosson J, 2016

    Journal: Clin Cancer Res
    Reference: Jul 15;22(14):3702

    paper

  • 619. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.

    Murtola T, Peltomaa A, Määtänen L, Taari K, Tammela T, Auvinen A, 2016

    Journal: Eur Urol Focus
    Reference: June 2.

    paper

  • 618. Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer.

    Kinnunen PT, Murtola TJ, Talala K, Taari K, Tammela TL, Auvinen A, 2016

    Journal: Scand J Urol
    Reference: Sep 14:1-7

    paper

  • 617. Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate Cancer.

    Kilpeläinen TP, Mäkinen T, Karhunen PJ, Aro J, Lahtela J, Taari K, Talala K, Tammela TL, Auvinen A, 2016

    Journal: Cancer Epidemiol
    Reference: Sep 13;45:1-5

    paper

  • 616. Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.

    Kaapu KJ, Murtola TJ, Määttänen L, Talala K, Taari K, Tammela TL, Auvinen A, 2016

    Journal: Cancer Causes Control
    Reference: Feb;27(2):157-64

    paper

  • 615. A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk.

    Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JA, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, Pollak MN, Price AJ, Roobol MJ, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Ziegler RG, Key TJ, Allen NE; Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group, 2016

    Journal: Cancer Res
    Reference: Apr 15;76(8):2288-300

    paper

  • 614. Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy.

    Kweldam CF, Kümmerlin IP, Nieboer D, Verhoef EI, Steyerberg EW, van der Kwast TH, Roobol MJ, van Leenders GJ, 2016

    Journal: Mod Pathol
    Reference: Jun;29(6):630-6

    paper

  • 613. Where we are with screening and risk prediction for prostate cancer in 2016.

    Roobol MJ, 2016

    Journal: BJU Int
    Reference: Mar;117(3):381

    paper

  • 612. Perspective: Enforce the clinical guidelines.

    Roobol M, 2015

    Journal: Nature
    Reference: Dec 17;528(7582):S123

    paper

  • 611. Prostate Specific Antigen as a Tumor Marker in Prostate Cancer: Biochemical and Clinical Aspects.

    Salman JW, Schoots IG, Carlsson SV, Jenster G, Roobol MJ, 2015

    Journal: Adv Exp Med Biol
    Reference: 867:93-114

  • 610. Unorganized prostate-specific antigen-based screening for prostate cancer: more harm than benefit. When will we finally start to implement guidelines and risk assessment tools in clinical practice?

    Roobol MJ, 2015

    Journal: Eur Urol
    Reference: Sep;68(3):363-4

    paper

  • 609. Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?

    Bokhorst LP, Venderbos LD, Schröder FH, Bangma CH, Steyerberg EW, Roobol MJ, 2015

    Journal: J Urol
    Reference: Aug;194(2):336-42

    paper

  • 608. Ethnicity and prostate cancer: the way to solve the screening problem?

    Bokhorst LP, Roobol MJ, 2015

    Journal: BMC Med
    Reference: Aug 4;13:179

    paper

  • 607. [Early detection of prostate cancer–recommendations after 13 years of follow-up in the European randomised study].

    Schröder FH, Roobol MJ, Bangma CH, 2015

    Journal: Ned Tijdschr Geneeskd
    Reference: 159:A8677

Next →